Intercept Pharmaceuticals, Inc. ICPT was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $110.35 – $120.68 in the past one-month time frame, witnessed a sharp increase yesterday.
The move came after the company reported positive results from its Regenerate phase 3 clinical study.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Intercept Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Intercept Pharmaceuticals, Inc. Price
Intercept Pharmaceuticals, Inc. Price | Intercept Pharmaceuticals, Inc. Quote
A better-ranked stock in the Medical – Biomedical and Genetics industry is Celgene Corporation CELG, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ICPT going up? Or down? Predict to see what others think: Up or Down
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celgene Corporation (CELG) : Free Stock Analysis Report
Intercept Pharmaceuticals, Inc. (ICPT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research